Zobrazeno 1 - 10
of 184
pro vyhledávání: '"Lisa Argnani"'
Autor:
Gianmarco Bagnato, Vittorio Stefoni, Alessandro Broccoli, Lisa Argnani, Cinzia Pellegrini, Beatrice Casadei, Francesca Bonifazi, Pier Luigi Zinzani
Publikováno v:
Mediterranean Journal of Hematology and Infectious Diseases, Vol 16, Iss 1 (2024)
We report the case of 2 patients with relapsed/refractory peripheral T-cell lymphoma treated with valemetostat tosilate, a selective dual inhibitor of histone-lysine N-methyltransferases enhancer of zeste homolog 1 and 2, and subsequently bridged to
Externí odkaz:
https://doaj.org/article/f3bcfe6454db4c48926e6d674464f884
Autor:
Chiara Rusconi, Francesca Ricci, Rosa Daffini, Beatrice Casadei, Vittorio Ruggero Zilioli, Federico Mazzon, Vincenzo Marasco, Eleonora Calabretta, Chiara Pagani, Lisa Argnani, Cristina Muzi, Anna Guidetti, Marcello Rodari, Angela Passi, Sara Iadecola, Roberto Cairoli, Pier Luigi Zinzani, Alessandro Re, Paolo Corradini, Armando Santoro
Publikováno v:
HemaSphere, Vol 7, p e95482eb (2023)
Externí odkaz:
https://doaj.org/article/9a4e2f39574042ee85a7f5513557a15a
Autor:
Lisa Argnani, Beatrice Casadei, Carla Pelusi, Valentina Lo Preiato, Uberto Pagotto, Francesco Bertoni, Pier Luigi Zinzani
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-7 (2022)
Abstract Immune checkpoint inhibitors (ICIs) show efficacy in the treatment of non-Hodgkin lymphomas (NHL). However, these agents are associated with a unique group of side effects called immune-related adverse events (irAEs). We conducted an observa
Externí odkaz:
https://doaj.org/article/c4a432eb5a404a069eb0b4e8270968c9
Autor:
Lisa Argnani, Alessandro Broccoli, Cinzia Pellegrini, Alberto Fabbri, Benedetta Puccini, Riccardo Bruna, Maria Chiara Tisi, Francesco Masia, Leonardo Flenghi, Maria Elena Nizzoli, Maurizio Musso, Marilena Salerno, Potito Rosario Scalzulli, Daniela Dessi’, Isacco Ferrarini, Elsa Pennese, Elisa Lucchini, Francesca Gaia Rossi, Carla Minoia, Filippo Gherlinzoni, Pellegrino Musto, Caterina Patti, Vittorio Stefoni, Pier Luigi Zinzani
Publikováno v:
HemaSphere, Vol 6, Iss 12, p e798 (2022)
After FDA and EMA approval of the regimen containing polatuzumab vedotin plus rituximab and bendamustine (PolaBR), eligible relapsed/refractory diffuse large B-cell lymphoma (DLBCL) patients in Italy were granted early access through a Named Patient
Externí odkaz:
https://doaj.org/article/1cc1af983bd1486091a4adbd8c7747a9
Autor:
Beatrice Casadei, Lisa Argnani, Alice Morigi, Ginevra Lolli, Alessandro Broccoli, Cinzia Pellegrini, Laura Nanni, Vittorio Stefoni, Paolo E. Coppola, Matteo Carella, Michele Cavo, Pier Luigi Zinzani
Publikováno v:
Cancer Medicine, Vol 9, Iss 21, Pp 7830-7836 (2020)
Abstract Programmed death‐1 (PD1) blockade is an efficient and safe therapeutic option in patients with relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL). However, a substantial proportion of patients’ progresses or loses the response to
Externí odkaz:
https://doaj.org/article/59e93f11c511493180f4ed9f296c34cc
Autor:
Miriam Marangon, Beatrice Casadei, Alessandro Broccoli, Lisa Argnani, Michele Cavo, Pier Luigi Zinzani
Publikováno v:
Clinical Case Reports, Vol 8, Iss 6, Pp 933-937 (2020)
Abstract In primary mediastinal large B‐cell lymphoma, central nervous system (CNS) relapse is an uncommon event with a dismal prognosis. We report about the successful management of CNS relapse with chemoimmunotherapy according to MATRix (methotre
Externí odkaz:
https://doaj.org/article/0c827ce488794903a226759198cc5064
Autor:
Lisa Argnani, Anna Zanetti, Greta Carrara, Ettore Silvagni, Giulio Guerrini, Antonella Zambon, Carlo Alberto Scirè
Publikováno v:
Frontiers in Medicine, Vol 8 (2021)
Background: Rheumatoid arthritis (RA) is associated with an increase in cardiovascular (CV) risk. This issue maybe not only explained by a genetic component, as well as by the traditional CV risk factors, but also by an underestimation and undertreat
Externí odkaz:
https://doaj.org/article/0004ed958c1340d4910f81733d729521
Publikováno v:
BMJ Open, Vol 10, Iss 9 (2020)
Objective To describe the adherence to quality of care indicators in early rheumatoid arthritis (RA) and to evaluate its impact on the risk of hospitalisation in a real-world setting.Design Retrospective cohort study.Setting Patients with early-onset
Externí odkaz:
https://doaj.org/article/26e42cecd6444e7381e2720148615bcb
Publikováno v:
Mediterranean Journal of Hematology and Infectious Diseases, Vol 12, Iss 1 (2020)
Background: Sézary syndrome (SS) is a rare lymphoproliferative neoplasm, almost incurable outside the setting of allogeneic transplantable patients. Prognosis for relapse/refractory patient remains poor, as the available drugs confer short lasting r
Externí odkaz:
https://doaj.org/article/ee6b9b446f4347558cc37d9655233ae4
Autor:
Vittorio Stefoni, Miriam Marangon, Alessandro Re, Arben Lleshi, Maurizio Bonfichi, Antonello Pinto, Nicola Bianchetti, Cinzia Pellegrini, Lisa Argnani, Pier Luigi Zinzani
Publikováno v:
Haematologica, Vol 105, Iss 10 (2020)
Externí odkaz:
https://doaj.org/article/62ca266e777f4117ad9ca9001d34a070